{"prompt": "['Renal', 'Serum creatinine OR', '<1.5 X ULN OR', 'Measured or calculated creatinine clearance', '> 40 mL/min @> 0.67 mL/sec) for participant', '(GFR can also be used in place of creatinine or', 'with creatinine levels >1.5 X institutional ULN', 'CrCl)', 'Hepatic', 'Total bilirubin', '<1.5 xULN OR direct bilirubin >ULN for', 'participants with total bilirubin levels', '>1.5 X ULN', 'AST and ALT', '<3 X ULN (5 X ULN for participants with', 'liver metastases)', 'ALT = alanine aminotransferase; AST =aspartate aminotransferase; GFR=glomerular filtration rate;', 'ULN=upper limit of normal', 'a Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC)', 'transfusion within last 4 weeks.', 'b Creatinine clearance (CrCl) calculated per the Cockcroft and Gault formula', 'Males: (140 - age) X weight (kg)/(serum creatinine [mg/dL] X 72)', 'Females: [(140 - age) X weight (kg)/(serum creatinine [mg/dL] X 72) X 0.85', '7. Female participants:', 'a.', 'All females must have a negative serum or urine pregnancy test (minimum', 'sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [\u00df-', 'hCG]) at the Screening Visit and the Baseline Visit. A pregnancy test needs to be', 'performed within 72 hours of the first dose of study drug. Women of childbearing', 'potential (WOCBP) must agree to use a highly effective method of contraception', 'for the entire study period and for 120 days after study discontinuation as', 'described in Appendix 3.', '8. Male participants:', 'a.', 'Male subjects who are partners of women of childbearing potential must use a', 'condom and their female partners of childbearing potential must use a highly', 'effective method of contraception beginning at least 1 menstrual cycle prior to', 'starting study drugs, throughout the entire study period, and for 120 days after the', 'last dose of study drug, unless the male subjects are totally sexually abstinent or', 'have undergone a successful vasectomy with confirmed azoospermia or unless the', 'female partners have been sterilized surgically or are otherwise proven sterile', '(Appendix 3).', 'Page 12', 'Version Date: 05/08/2020']['5.1.2 Participant Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', '1. Evidence of metastatic disease on pre-treatment imaging', '2. The subject has received of any type of cytotoxic, biologic or other systemic anticancer', 'therapy for kidney cancer', '3. The subject has received any other type of investigational agent within 28 days before the', 'first dose of study treatment', '4.', 'Excluding the primary tumor leading to enrollment in this study, any other active', 'malignancy (except for localized prostate cancer, definitively treated melanoma in-situ,', 'basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or', 'cervix) within the past 24 months;', '5. Prior treatment with lenvatinib or any agent directed against PD-1, PD-L1 or PD-L2, or', 'another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137)', '6. Is pregnant or breastfeeding, or expecting to conceive or father children within the', 'projected duration of the study, starting with the screening visit through 120 days after', 'the last dose of trial treatment.', '7.', 'Subjects having > >1+ proteinuria on urinalysis will undergo 24-hour urine collection for', 'quantitative assessment of proteinuria. Subjects with urine protein >1 g/24-hour will be', 'ineligible.', '8. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that', 'might affect the absorption of lenvatinib', '9. The subject has uncontrolled, significant intercurrent or recent illness including, but not', 'limited to, the following conditions:', 'a.', 'Cardiovascular disorders:', 'i. New York Heart Association congestive heart failure of grade II or above,', 'unstable angina, myocardial infarction within the past 6 months, or serious', 'cardiac arrhythmia associated with significant cardiovascular impairment', 'within the past 6 months', 'ii.', 'Uncontrolled hypertension defined as sustained blood pressure (BP) >', '150 mm Hg systolic or > 90 mm Hg diastolic despite optimal', 'antihypertensive treatment', 'iii. Prolongation of QTc interval to >480 msec per electrocardiogram (ECG)', 'Page 13', 'Version Date: 05/08/2020']\n\n###\n\n", "completion": "END"}